Author:
Zheng Qiao,Zhou Tiecheng,Ding Weijun
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics,2020. CA-Cancer J Clin 70(1):7–30
2. Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into Molecular classifications of Triple-negative breast Cancer: improving patient selection for treatment. Cancer Discov 9:176–198
3. Laimito KR, Gámez-Pozo A, Sepúlveda J et al (2016) Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. E cancer Med Sci 10:632
4. Bardia A, Mayer IA, Diamond JR et al (2017) Efficacy and safety of anti-trop-2 antibody drugconjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatictriple-negative breast cancer. J Clin Oncol 35:2141–2148
5. O’Shaughnessy J, Schwartzberg L, Danso MA et al (2014) Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 32(34):3840–3847